Caribou Biosciences (NASDAQ:CRBU) Announces Earnings Results, Beats Estimates By $0.05 EPS

Caribou Biosciences (NASDAQ:CRBU) issued its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05, FiscalAI reports. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The company had revenue of $3.94 million for the quarter, compared to the consensus estimate of $1.96 million.

Caribou Biosciences Stock Performance

Shares of CRBU traded down $0.09 during mid-day trading on Thursday, hitting $1.71. The company’s stock had a trading volume of 1,079,460 shares, compared to its average volume of 1,267,293. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.54. The stock’s 50-day moving average is $1.64 and its two-hundred day moving average is $1.90. The firm has a market capitalization of $159.83 million, a PE ratio of -1.01 and a beta of 2.54.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HC Wainwright boosted their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Planning bought a new stake in shares of Caribou Biosciences in the second quarter valued at about $25,000. Hudson Bay Capital Management LP acquired a new position in Caribou Biosciences in the 2nd quarter valued at approximately $30,000. Russell Investments Group Ltd. boosted its holdings in Caribou Biosciences by 80.0% during the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock valued at $39,000 after purchasing an additional 10,824 shares in the last quarter. Credit Agricole S A acquired a new position in shares of Caribou Biosciences in the 3rd quarter worth approximately $68,000. Finally, US Bancorp DE lifted its position in shares of Caribou Biosciences by 18,624.0% during the 3rd quarter. US Bancorp DE now owns 34,265 shares of the company’s stock worth $80,000 after buying an additional 34,082 shares during the period. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.